Clinicopathological characteristics and prognostic factors in young patients after hepatectomy for hepatocellular carcinoma

World Journal of Surgical Oncology

Akinobu Taketomi¹  Hirofumi Kamachi¹  Tatsuhiko Kakisaka¹  Yosuke Tsuruga¹  Kenji Wakayama¹  Hideki Yokoo¹  Toshiya Kamiyama¹  Shingo Shimada¹ 

[1] Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita15-Nishi7, Kita-Ku, 060-8638, Sapporo, Hokkaido, Japan

关键词: Prognostic factors;    Clinicopathological characteristics;    Hepatectomy;    Young;    Hepatocellular carcinoma;   

Others  :  826120
DOI  :  10.1186/1477-7819-11-52

 received in 2012-10-11, accepted in 2013-02-06,  发布年份 2013

【 摘 要 】

Background

The aim of this study was to analyze the clinicopathological characteristics and the prognostic factors for survival and recurrence of young patients who had undergone hepatectomy for hepatocellular carcinoma.

Methods

Between 1990 and 2010, 31 patients aged 40 years or younger (younger patient group) among 811 consecutive patients with hepatocellular carcinoma who had undergone primary hepatectomy were analyzed with regard to patient factors, including liver function, tumor factors and operative factors. The clinicopathological characteristics of the younger patients were compared with those of patients over the age of 40 (older patient group). Then the prognostic factors of the younger patients were analyzed. Continuous variables were expressed as the means ± standard deviation and compared using the χ² test for categorical variables. Overall survival and recurrence-free survival rates were determined by the Kaplan-Meier method and analyzed by the log-rank test. The Cox proportional hazards model was used for multivariate analysis.

Results

In the younger patients, the rates of HBs-antigen-positivity, high alpha-fetoprotein, portal invasion, intrahepatic metastasis, large tumors, low indocyanin green retention rate at 15 minutes, and anatomical resection were significantly higher than the same measures in the older patients. The five-year overall survival rate of the young patients was 49.6%. The prognostic factors of survival were HCV-antibody-positivity and low albumin status. Prognostic factors of recurrence were multiple tumors and the presence of portal invasion.

Conclusions

In younger patients, survival appeared to be primarily affected by liver function, while recurrence was affected by tumor factors. Young patients with hepatocellular carcinoma should be aggressively treated with hepatectomy due to their good pre-surgical liver function.

【 授权许可】

   
2013 Shimada et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [2]Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP: National trends and disparities in the incidence of hepatocellular carcinoma,1998-2003. Prev Chronic Dis 2008, 5:A74.
• [3]Furuta T, Kanematsu T, Matsumata T, Shirabe K, Yamagata M, Utsunomiya T, Sugimachi K: Clinicopathologic features of hepatocellular carcinoma in young patients. Cancer 1990, 66:2395-2398.
• [4]Lam CM, Chan AO, Ho P, Ng IO, Lo CM, Liu CL, Poon RT, Fan ST: Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening. Aliment Pharmacol Ther 2004, 19:771-777.
• [5]Sezaki H, Kobayashi M, Hosaka T, Someya T, Akuta N, Suzuki F, Tsubota A, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Sato J, Kumada H: Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection. J Gastroenterol 2004, 39:550-556.
• [6]Klein WM, Molmenti EP, Colombani PM, Grover DS, Schwarz KB, Boitnott J, Torbenson MS: Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol 2005, 124:512-518.
• [7]Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW, Rhee JC: Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol 2006, 21:588-594.
• [8]Chen CH, Chang TT, Cheng KS, Su WW, Yang SS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN: Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 2006, 26:766-773.
• [9]Cho SJ, Yoon JH, Hwang SS, Lee HS: Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 2007, 22:1226-1231.
• [10]Yamazaki Y, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Abe T, Katakai K, Kojima A, Matsuzaki Y, Mori M: Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis. Dig Dis Sci 2007, 52:1103-1107.
• [11]Chang PE, Ong WC, Lui HF, Tan CK: Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol 2008, 43:881-888.
• [12]Takeishi K, Shirabe K, Muto J, Toshima T, Taketomi A, Maehara Y: Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy. World J Surg 2011, 35:1063-1071.
• [13]Tanioka H, Omagari K, Kato Y, Nakata K, Kusumoto Y, Mori I, Furukawa R, Tajima H, Koga M, Yano M, Kohno S: Present status of hepatitis virus-associated hepatocellular carcinoma in Nagasaki Prefecture, Japan: a cross-sectional study of 1019 patients. J Infect Chemother 2002, 8:64-69.
• [14]Aramaki M, Kawano K, Sasaki A, Ohno T, Tahara K, Kai S, Iwashita Y, Kitano S: Hepatocellular carcinoma in young adults. Hepatogastroenterology 2005, 52:1795-1797.
• [15]Kew MC: Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: evidence from southern Africa. Hepatology 1981, 1:366-369.
• [16]Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamashita K, Taniguchi M, Shimamura T, Matsushita M, Todo S: Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg 2010, 211:443-449.
• [17]Dan YY, Aung MO, Lim SG: The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008, 2:284-295.
• [18]Ni YH, Chang MH, Hsu HY, Hsu HC, Chen CC, Chen WJ, Lee CY: Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis. Cancer 1991, 68:1737-1741.
• [19]Hernandez-Castillo E, Mondragon-Sanchez R, Garduno-Lopez AL, Gomez-Gomez E, Ruiz-Molina JM, Onate-Ocana LF, Bernal-Maldonado R: Hepatocellular carcinoma in the youth. A comparative analysis with hepatocellular carcinoma in adulthood. Hepatogastroenterology 2005, 52:903-907.
• [20]Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, Lam CM, Ng KK, Chan SC: Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011, 253:745-758.
• [21]Yang T, Lin C, Zhai J, Shi S, Zhu M, Zhu N, Lu JH, Yang GS, Wu MC: Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin Oncol 2012, 138:1121-1129.
• [22]Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004, 112:44-50.
• [23]Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M: The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009, 44:991-999.
• [24]Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ: A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010, 17:179-185.
• [25]Ismail H, Broniszczak D, Kalicinski P, Markiewicz-Kijewska M, Teisseyre J, Stefanowicz M, Szymczak M, Dembowska-Baginska B, Kluge P, Perek D, Kosciesza A, Dzik E, Lembas A, Teisserye M: Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant 2009, 13:682-692.
• [26]Romano F, Stroppa P, Bravi M, Casotti V, Lucianetti A, Guizzetti M, Sonzogni A, Colledan M, D'Antiga L: Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transplant 2011, 15:573-579.
• [27]Saab S, McTigue M, Finn RS, Busuttil RW: Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant 2010, 8:307-313.